RASON promotes KRAS^G12C-driven tumor progression and immune evasion in non-small cell lung cancer.

ABSTRACT:

Background

KRAS is the most frequently mutated oncogene in human cancers, with KRAS^G12C being a prevalent driver mutation in 12-13% non-small cell lung cancer (NSCLC) cases. Despite breakthroughs in KRAS^G12C inhibitors such as sotorasib (AMG-510) and adagrasib (MRTX-849), clinical resistance remains a challenging issue, highlighting the need for deeper understanding of the molecular mechanisms underlying KRAS^G12C-driven oncogenic signaling in NSCLC. Previously, we identified RASON as a novel regulator of KRAS^G12D/V signaling in pancreatic cancer. Herein, we aim to explore the role of RASON in KRAS^G12C-driven NSCLC and its therapeutic potential.

Methods

Immunohistochemistry analysis of NSCLC patient cohorts was performed

SUBMITTER: Wu J 

PROVIDER: S-EPMC11934775 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature